ByTrending Posts
Can Bristol Myers Squibb’s $330 Million AI Investment…
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Can GSK’s $340 Million AI Investment in 2025…
Global – December 31, 2025 — GlaxoSmithKline plc (GSK) significantly expanded its use of artificial intelligence (AI) throughout…
Can AstraZeneca’s $390 Million AI Investment in 2025…
Global – December 31, 2025 — AstraZeneca plc significantly expanded its commitment to artificial intelligence (AI) throughout 2025,…
Can Merck’s $300 Million AI Investment in 2025…
Global – December 31, 2025 — Merck & Co., Inc. significantly expanded its commitment to artificial intelligence (AI)…
Can Gilead’s $260 Million AI Investment in 2025…
Global – December 31, 2025 — Gilead Sciences, Inc. expanded its commitment to artificial intelligence (AI) throughout 2025…
Can Sanofi’s $380 Million AI Investment in 2025…
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
Can Roche’s $420 Million AI Investment in 2025…
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and diagnostics, significantly expanded…
Can Novartis’ $480 Million AI Investment in 2025…
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across…
Can Johnson & Johnson’s $350 Million AI Investment…
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial intelligence (AI) across…
Trending Posts
Latest Stories
Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration…
Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug…
Gallery
